Treating brain tumors has always been constrained by one major challenge: how to reach the tumor effectively without causing additional harm. The blood–brain barrier, while essential for protecting the brain, also limits the impact of many promising therapies.
Recent preclinical research suggests an intriguing possibility—intranasal delivery of immunotherapy.
In experimental models of glioblastoma, researchers tested gold nanoparticle–based spherical nucleic acids (ISD45-SNAs) delivered as nasal drops. These particles are designed to activate the cGAS–STING pathway, a fundamental immune signaling mechanism that helps the body recognize and attack cancer cells.
Key observations from animal studies:
- Nasal delivery enabled treatment to reach brain tumors noninvasively
- Strong activation of anti-tumor immune responses within the brain
- Significant suppression of tumor growth and prolonged survival
- When combined with immune checkpoint inhibitors, complete tumor control and durable immune memory were observed
What makes this approach particularly compelling is its non-invasive nature, potential to bypass the blood–brain barrier, and compatibility with existing immunotherapy platforms.
It is essential to note that these findings remain preclinical. Clinical trials will be required to confirm safety, feasibility, and benefit in patients. However, for a disease as challenging as glioblastoma, even incremental progress grounded in strong science matters.
Innovation in oncology must always be balanced with rigor—and this work represents an encouraging step in that direction.
Selected references:
- Nature Nanotechnology – Spherical nucleic acids in brain tumor immunotherapy
- Science Translational Medicine – cGAS–STING pathway targeting in glioblastoma
- Clinical Cancer Research – Immunotherapy advances in high-grade gliomas